|Articles|May 1, 2010
CROs Improve Service Delivery
Author(s)Industry Standard Research
ISR Reports' data show the CRO industry is improving service delivery, albeit with room for improvement. Not long ago- perhaps as recent as 2005-this chart would have been reversed, when more service providers were missing expectations than exceeding them.
Advertisement
ISR Reports' data show the CRO industry is improving service delivery, albeit with room for improvement. Not long ago— perhaps as recent as 2005—this chart would have been reversed, when more service providers were missing expectations than exceeding them.
So why the change? We have identified the following three factors:
- The increasingly competitive CRO environment is responsible for some of the quality improvements. Disaffected customers have more options than they used to, providing CROs with all the incentive needed to tighten the bolts on their clinical operations machinery.
- Similarly, CROs are getting better at asking the right questions and identifying their customers' needs.
- And for their part, we would suggest that sponsors are also becoming more sophisticated outsourcers They are getting better at articulating their needs, making it more likely that CROs can meet them.
Sponsors Rate Satisfaction with CROs
With 20% of interactions still missing expectations more can be done. But in our experience, these relationships have come a long way—Industry Standard Reports, www.ISRreports.com
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug TrialsSeptember 11th 2025
How ClinOps Teams Should Evaluate GenAI Tools in Trial DiscoverySeptember 11th 2025
How Recent Policy Changes Could Impact Clinical ResearchSeptember 10th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
3
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
4
How Recent Policy Changes Could Impact Clinical Research
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
